Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
(Date:5/29/2015)... , May 29, 2015  Caris Life ... two studies in which researchers utilized Caris Molecular ... to identify potential therapeutic targets in patients with ... of the programmed cell death protein 1 (PD-1) ... June 1 at the 2015 American Society of ...
(Date:5/29/2015)... TRIANGLE PARK, N.C. , May 29, 2015 ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer ... the company,s business at the Jefferies 2015 Global Healthcare Conference ... The presentation and the immediately following Q&A session will take ... Time, and can be accessed via a live webcast on ...
(Date:5/29/2015)... Translation is frequently listed as one of the ... used in a way that is right for a company, ... product or service offering. , Here are some of ... on a company's bottom line: , 1.    Attract bigger audience. , ... can use, why not offer it globally? Nelson Mandela once ...
Breaking Biology Technology:Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Three Ways Translation Can Help Businesses Grow 2
... Pa., June 23 Environmental Tectonics Corporation (OTC Bulletin ... their BioMedical Division will be exhibiting at the upcoming ... an international, non-profit organization and is the primary source ... worldwide. , , The 2009 Annual UHMS meeting ...
... For NDA and to Complete Current Phase 3 Trial ... BETHESDA, Md., June 23 Spherix Incorporated (Nasdaq: ... therapy, and a provider of technical and regulatory consulting ... announced that it has received its first full-scale production ...
... Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ... involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin), showed ... survival rate against an inhaled lethal dose of anthrax. ... 16 mg/kg once-a-day (the human equivalent dose of 300 ...
Cached Biology Technology:Environmental Tectonics Corporation's BioMedical Division to Exhibit at Undersea and Hyperbaric Medical Society Meeting 2Environmental Tectonics Corporation's BioMedical Division to Exhibit at Undersea and Hyperbaric Medical Society Meeting 3Environmental Tectonics Corporation's BioMedical Division to Exhibit at Undersea and Hyperbaric Medical Society Meeting 4Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 2Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 3
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... the "Fingerprint Sensors Market in Smart Mobile Devices ... report believes that 2014 was a watershed year for ... introduction of ,Apple Pay,. Apple gave fingerprint sensors a ... payment service. Fingerprint sensors are a must-have feature in ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... and Matthew Champion from the University of Notre Dame,s ... to directly detect bacterial protein secretion, which could provide ... The Champions point out that bacteria ... beyond their cell membrane in order to interact with ...
... by several orders of magnitude. The molecular mechanism by which ... and thus slows cell growth is described by biophysicists at ... the Online Early Edition of the journal PNAS . ... showed that Ras puts a phosphate chain under tension to ...
... MA A new article published today in ... evidence to suggest the current obesity epidemic in the ... high fructose corn syrup (HFCS). The commentary concludes ... research, there is overwhelming evidence showing HFCS is nutritionally ...
Cached Biology News:Notre Dame research could provide new insights into tuberculosis and other diseases 2RUB researchers clarify catalysis mechanism of cell growth protein Ras 2RUB researchers clarify catalysis mechanism of cell growth protein Ras 3Scientists conclude high fructose corn syrup should not be blamed for obesity 2
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
For the development of an immunoprecipitation assay to measure Chk1 kinase activity in cell lysates....
Non-Protein Peroxidase Stabilizer , 1 L...
... Gelzyme is an agarose-digesting enzyme isolated ... simple carbohydrate bonds in agarose producing ... gel. The remaining carbohydrate molecules will ... DNA isolated with Gelzyme enzyme can ...
Biology Products: